

SIERRA LEONE – Co-financing waiver for Yellow Fever vaccines within post-ebola EPI Recovery Plan

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Sierra Leone																					
2. Grant Number: 0715-SLE-06b-X																					
3. Date of Decision Letter: 3 September 2015																					
4. Date of the Partnership Framework Agreement: 31 October 2013																					
5. Programme Title: NVS, Yellow Fever Routine																					
6. Vaccine type: Yellow Fever																					
7. Requested product presentation and formulation of vaccine: Yellow Fever, 10 dose(s) per vial, LYOPHILISED																					
8. Programme Duration¹⁵: 2003 - 2015																					
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):																					
<table border="1" style="margin: auto; border-collapse: collapse;"> <thead> <tr> <th style="width: 30%;"></th> <th style="width: 20%;">2003-2014</th> <th style="width: 20%;">2015</th> <th style="width: 30%;">Total¹⁶</th> </tr> </thead> <tbody> <tr> <td style="padding: 5px;">Programme Budget (US\$)</td> <td style="padding: 5px; text-align: center;">US\$2,087,090¹⁷</td> <td style="padding: 5px; text-align: center;">US\$243,000</td> <td style="padding: 5px; text-align: center;">US\$2,330,090</td> </tr> </tbody> </table>		2003-2014	2015	Total ¹⁶	Programme Budget (US\$)	US\$2,087,090 ¹⁷	US\$243,000	US\$2,330,090													
	2003-2014	2015	Total ¹⁶																		
Programme Budget (US\$)	US\$2,087,090 ¹⁷	US\$243,000	US\$2,330,090																		
10. Vaccine Introduction Grant: Not applicable.																					
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):¹⁸																					
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 50%;"></th> <th style="width: 25%;">2003-2014</th> <th style="width: 25%;">2015</th> </tr> </thead> <tbody> <tr> <td style="padding: 5px;">Type of supplies to be purchased with Gavi funds in each year</td> <td></td> <td></td> </tr> <tr> <td style="padding: 5px;">Number of Yellow Fever vaccines doses</td> <td></td> <td style="text-align: center;">215,000</td> </tr> <tr> <td style="padding: 5px;">Number of AD syringes</td> <td></td> <td style="text-align: center;">210,300</td> </tr> <tr> <td style="padding: 5px;">Number of re-constitution syringes</td> <td></td> <td style="text-align: center;">23,700</td> </tr> <tr> <td style="padding: 5px;">Number of safety boxes</td> <td></td> <td style="text-align: center;">2,575</td> </tr> <tr> <td style="padding: 5px;">Annual Amounts (US\$)</td> <td style="text-align: center;">US\$2,087,090¹⁹</td> <td style="text-align: center;">US\$243,000</td> </tr> </tbody> </table>		2003-2014	2015	Type of supplies to be purchased with Gavi funds in each year			Number of Yellow Fever vaccines doses		215,000	Number of AD syringes		210,300	Number of re-constitution syringes		23,700	Number of safety boxes		2,575	Annual Amounts (US\$)	US\$2,087,090 ¹⁹	US\$243,000
	2003-2014	2015																			
Type of supplies to be purchased with Gavi funds in each year																					
Number of Yellow Fever vaccines doses		215,000																			
Number of AD syringes		210,300																			
Number of re-constitution syringes		23,700																			
Number of safety boxes		2,575																			
Annual Amounts (US\$)	US\$2,087,090 ¹⁹	US\$243,000																			
12. Procurement agency: UNICEF																					

¹⁵ This is the entire duration of the programme.

¹⁶ This is the total amount endorsed by Gavi for the entire duration of the programme. This should be equal to the total of all sums in the table.

¹⁷ This is the consolidated amount for all previous years.

¹⁸ This is the amount that Gavi has approved.

¹⁹ This is the consolidated amount for all previously approved years.

13. Self-procurement: Not applicable.		
14. Co-financing obligations: The co-financing requirements for 2014 and 2015 have been waived.		
Type of supplies to be purchased with Country funds in each year	2014	2015
Number of vaccine doses	0	0
Value of vaccine doses (US\$)	US\$0	US\$0
Total Co-Financing Payments (US\$) (including freight)	US\$0	US\$0
15. Operational support for campaigns: Not applicable		
16. Additional documents to be delivered for future disbursements: Not applicable		
17. Financial Clarifications: The Country shall provide the following clarifications to Gavi*: Not applicable.		
<i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i>		
18. Other conditions: Not applicable.		

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes

3 September 2015

SIERRA LEONE – Co-financing waiver for Pentavalent vaccines within post-ebola EPI Recovery Plan

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Sierra Leone			
2. Grant Number: 0815-SLE-04c-X			
3. Date of Decision Letter: 3 September 2015			
4. Date of the Partnership Framework Agreement: 31 October 2013			
5. Programme Title: NVS, Pentavalent Routine			
6. Vaccine type: Pentavalent			
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 10 dose(s) per vial, LIQUID			
8. Programme Duration⁵: 2007 - 2015			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2007-2014	2015	Total ⁶
Programme Budget (US\$)	US\$14,580,135 ⁷	US\$1,351,500	US\$15,931,635
10. Vaccine Introduction Grant: Not applicable.			
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁸			
Type of supplies to be purchased with Gavi funds in each year	2007-2014	2015	
Number of Pentavalent vaccines doses		663,500	
Number of AD syringes		691,700	
Number of safety boxes		7,625	
Annual Amounts (US\$)	US\$14,580,135 ⁹	US\$1,351,500	
12. Procurement agency: UNICEF			
13. Self-procurement: Not applicable.			

⁵ This is the entire duration of the programme.

⁶ This is the total amount endorsed by Gavi for the entire duration of the programme. This should be equal to the total of all sums in the table.

⁷ This is the consolidated amount for all previous years.

⁸ This is the amount that Gavi has approved.

⁹ This is the consolidated amount for all previously approved years.

14. Co-financing obligations: The co-financing requirements for 2014 and 2015 have been waived.		
Type of supplies to be purchased with Country funds in each year	2014	2015
Number of vaccine doses	0	0
Value of vaccine doses (US\$)		
Total Co-Financing Payments (US\$) (including freight)	US\$0	US\$0
15. Operational support for campaigns: Not applicable		
16. Additional documents to be delivered for future disbursements: Not applicable		
17. Financial Clarifications: The Country shall provide the following clarifications to Gavi*: Not applicable. <i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i>		
18. Other conditions: Not applicable.		

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes

3 September 2015

SIERRA LEONE – Co-financing waiver for Pneumococcal vaccines within post-ebola EPI Recovery Plan

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Sierra Leone			
2. Grant Number: 1215-SLE-12c-X			
3. Date of Decision Letter: 3 September 2015			
4. Date of the Partnership Framework Agreement: 31 October 2013			
5. Programme Title: NVS, Pneumococcal Routine			
6. Vaccine type: Pneumococcal			
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial , LIQUID			
8. Programme Duration¹: 2010 - 2015			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2010-2014	2015	Total ²
Programme Budget (US\$)	US\$16,579,752	US\$2,374,500	US\$18,954,252
10. Vaccine Introduction Grant: Not applicable			
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):³			
Type of supplies to be purchased with Gavi funds in each year	2010-2014	2015	
Number of Pneumococcal vaccines doses		567,000	
Number of AD syringes		592,100	
Number of safety boxes		6,525	
Annual Amounts (US\$)	US\$16,579,752 ⁴	US\$2,374,500	
12. Procurement agency: UNICEF			
13. Self-procurement: Not applicable			

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme. This should be equal to the total of all sums in the table.

³ This is the amount that Gavi has approved.

⁴ This is the consolidated amount for all previously approved years.

14. Co-financing obligations: The co-financing requirements for 2014 and 2015 have been waived.			
Type of supplies to be purchased with Country funds in each year	2013	2014	2015
Number of vaccine doses	27,000	0	0
Value of vaccine doses (US\$)	US\$92,378		
Total Co-Financing Payments (US\$) (including freight)	US\$98,000	0	0
15. Operational support for campaigns: Not applicable			
16. Additional documents to be delivered for future disbursements: Not applicable			
17. Financial Clarifications: The Country shall provide the following clarifications to Gavi*: Not applicable. <i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i>			
18. Other conditions: Not applicable.			

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes

3 September 2015

SIERRA LEONE – Co-financing waiver for Rotavirus vaccines within post-ebola EPI Recovery Plan

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Sierra Leone									
2. Grant Number: 1215-SLE-13b-X									
3. Date of Decision Letter: 3 September 2015									
4. Date of the Partnership Framework Agreement: 31 October 2013									
5. Programme Title: NVS, Rotavirus Routine									
6. Vaccine type: Rotavirus									
7. Requested product presentation and formulation of vaccine: Rotavirus, 2 dose(s) schedule									
8. Programme Duration¹⁰: 2014 - 2015									
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement): <table border="1" style="margin: 10px auto; border-collapse: collapse; text-align: center;"> <thead> <tr> <th style="width: 30%;"></th> <th style="width: 20%;">2014</th> <th style="width: 20%;">2015</th> <th style="width: 30%;">Total¹¹</th> </tr> </thead> <tbody> <tr> <td style="text-align: left;">Programme Budget (US\$)</td> <td>US\$ 1,458,459¹²</td> <td>US\$679,000</td> <td>US\$2,137,459</td> </tr> </tbody> </table>		2014	2015	Total ¹¹	Programme Budget (US\$)	US\$ 1,458,459 ¹²	US\$679,000	US\$2,137,459	
	2014	2015	Total ¹¹						
Programme Budget (US\$)	US\$ 1,458,459 ¹²	US\$679,000	US\$2,137,459						
10. Vaccine Introduction Grant: Not applicable									
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):¹³ <table border="1" style="margin: 10px auto; border-collapse: collapse; text-align: center;"> <thead> <tr> <th style="width: 50%;">Type of supplies to be purchased with Gavi funds in each year</th> <th style="width: 25%;">2014</th> <th style="width: 25%;">2015</th> </tr> </thead> <tbody> <tr> <td style="text-align: left;">Number of Rotavirus vaccines doses</td> <td></td> <td>255,000</td> </tr> <tr> <td style="text-align: left;">Annual Amounts (US\$)</td> <td>US\$ 1,458,459¹⁴</td> <td>US\$679,000</td> </tr> </tbody> </table>	Type of supplies to be purchased with Gavi funds in each year	2014	2015	Number of Rotavirus vaccines doses		255,000	Annual Amounts (US\$)	US\$ 1,458,459 ¹⁴	US\$679,000
Type of supplies to be purchased with Gavi funds in each year	2014	2015							
Number of Rotavirus vaccines doses		255,000							
Annual Amounts (US\$)	US\$ 1,458,459 ¹⁴	US\$679,000							
12. Procurement agency: UNICEF									
13. Self-procurement: Not applicable.									

¹⁰ This is the entire duration of the programme.

¹¹ This is the total amount endorsed by Gavi for the entire duration of the programme. This should be equal to the total of all sums in the table.

¹² This is the consolidated amount for all previous years.

¹³ This is the amount that Gavi has approved.

¹⁴ This is the consolidated amount for all previously approved years.

14. Co-financing obligations: The co-financing requirements for 2014 and 2015 have been waived.

Type of supplies to be purchased with Country funds in each year	2014	2015
Number of vaccine doses	0	0
Value of vaccine doses (US\$)	US\$0	US\$0
Total Co-Financing Payments (US\$) (including freight)	US\$0	US\$0

15. Operational support for campaigns: Not applicable

16. Additional documents to be delivered for future disbursements: Not applicable

17. Financial Clarifications: The Country shall provide the following clarifications to Gavi*: Not applicable.

**Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements*

18. Other conditions: Not applicable.

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes

3 September 2015